Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL162936 | 0.82 | ALDH1A1 (0.52) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11856305 | 0.81 | TPMT (0.47) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2705458 | 0.81 | HDAC3 (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9416258 | 0.81 | LMNA (0.46) | TSHRCES2CES1ALDH1A1NPC1 | |
| SCHEMBL4832150 | 0.81 | ALDH1A1 (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11860544 | 0.81 | HDAC3 (0.54) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11852856 | 0.80 | MEN1 (0.49) | ALDH1A1ERCC5FEN1KDM4EKMT2A | |
| SCHEMBL9416273 | 0.79 | KMT2A (0.39) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10428977 | 0.79 | PLK1 (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9416229 | 0.77 | CES2 (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130345220-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM LLC (BM) | 2013-12-26 | — | — | US | disclosed |
| US-8569345-B2 | Compounds and compositions as LXR modulators | MOLTENI VALENTINA (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120214812-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM LLC (BM) | 2012-08-23 | — | — | US | disclosed |
| US-8158662-B2 | Compounds and compositions as LXR modulators | HAMILTON (BM) | 2012-04-17 | — | — | US | disclosed |
| CN-1918155-B | Compounds and compositions as LXR modulators | IRM LLC | 2010-05-26 | — | — | CN | disclosed |
| US-20090325981-A1 | Compounds and compositions as lxr modulators | IRM LLC (BM) | 2009-12-31 | — | — | US | disclosed |
| CN-1918155-A | Compounds and compositions as lxr modulators | IRM LLC (BM) | 2007-02-21 | — | — | CN | disclosed |
| EP-1713799-A2 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM, LLC (BM) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005077124-A2 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM LLC (BM) | 2005-08-25 | — | — | WO | disclosed |
| EP-0601520-A1 | Trifluorothymidine derivatives, process for producing the same and anti-cancer agent containing the same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1994-06-15 | — | — | EP | disclosed |
| US-4000147-A | ANTICONVULSANTS, CENTRAL NERVOUS SYSTEM DISORDERS | BASF AKTIENGESELLSCHAFT (DT) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345220-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | NR1H2, NR1H3, NR1H4 | HDAC3 112/4885HDAC4 493/4885HDAC1 323/4885 |
| US-20090325981-A1 | Compounds and compositions as lxr modulators | NR1H2, NR1H3, NR1H4 | HDAC3 112/4885HDAC4 493/4885HDAC1 323/4885 |
| US-20120214812-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | NR1H2, NR1H3, NR1H4 | HDAC3 112/4885HDAC4 493/4885HDAC1 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.